Efficacy and Safety of Trastuzumab Deruxtecan in the Treatment of HER2-Low/Positive Advanced Breast Cancer: A Single-Arm Meta-Analysis
June 2023
in “
Frontiers in Pharmacology
”
Studysummary This meta-analysis reports that trastuzumab deruxtecan is effective and has an acceptable safety profile for treating HER2-low or positive advanced breast cancer, although further research is recommended to support individualized treatment strategies.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on frontiersin.org →